Longitudinal studies allow a more accurate gauge of disease progression (Wong et al, 2020), and analysis of 27 FSHD patients over one year found no association between DUX4 target genes and FSHD clinical progression (Banerji, 2020; Wong et al, 2020). The gene discussed is DUX4; the disease is facioscapulohumeral muscular dystrophy.